Total: $104.308M | ||||
Company | Type Of | Number Of Shares, Units Or Warrants (M) | Amount | Investors; Placement Agents; |
|
| ||||
Advanced | Private | N/A | $0.836 | Advanced Viral completed an $836,000 private placement, mostly with existing shareholders (1/9) |
| ||||
Alizyme plc | Private | 57.5S | 16.1 | Alizyme raised US$26.4M in a placement of 57.5M new shares; the deal was underwritten by Nomura International plc and Canaccord Capital (1/29**) |
| ||||
Amarin Corp. | Private | 6.1S | $21.2 | Amarin raised $21.2M with the private placement of 6.1M shares to a group of accredited investors and management (1/28) |
| ||||
Antigenics | Private | 2.8S | $27.78 | Antigenics raised $27.78M in a private placement with an unnamed existing shareholder that was done concurrently with a public offering for a total raised of $62M (1/23) |
| ||||
Australian | Private | 6S | A$0.84 | Australian Cancer Technology issued 6M shares to raise US$492,889 before costs (1/16) |
Axonyx Inc. | Private | 6.5S | $4.9 | Axonyx raised gross proceeds of $4.9M through the sale of 6.5M shares of common stock to accredited investors; Punk, Ziegel & Co. acted as exclusive placement agent (1/6) |
BioMS Medical | Exercise of | 0.659W | C$2.6 | BioMS received US$1.7M in proceeds from the ex- ercise of about 658,700 share purchase warrants (1/14) |
DOR | Private | 10U | $1 | DOR raised $1M through a private placement of 10 units, each consisting of 285,714 shares of common stock and a warrant to purchase 142,857 shares at 75 cents per share (1/2) |
Evogene Ltd. | Private | N/A | $2 | Evogene raised $2M in a private placement with a group of Israeli, European and U.S. investors (1/6) |
Helix | Private | N/A | $1.5 | Helix BioMedix raised more than $1.5M in a private sale of common stock (1/23) |
InKine | Private | N/A | $3.8 | InKine raised $3.8M through a private placement with a group of accredited investors, led by Crestview Capital Funds and Ursus Capital Management LLC; board member Steven Ratoff also invested (1/2) |
Interleukin | Private | N/A | $0.5 | Interleukin completed an additional $500,000 interim financing in the form of a promissory note sold to an undisclosed consumer products company (1/30) |
LifeCell Corp. | Credit | N/A | -- | LifeCell secured a $4M credit facility through Silicon Valley Bank (1/30) |
Peptech Ltd. | Private | N/A | A$10 (US$5.8) | Peptech raised US$5.8M in a private placement with institutional investors (1/15**) |
Pheromone | Private | 2.14U | C$0.535 (US$0.343) | Pheromone raised US$342,725 with a private placement of 2.14M units at 25 cents per unit; each unit is exercisable into one common share of the company and one common share purchase warrant (1/7) |
Pro-Pharma- | Private | N/A | $3.9 | Pro-Pharmaceuticals completed a $3.9M private placement of common stock (1/15) |
SIGA | Private | 34U | $1.65 | SIGA raised $1.65M from an offering of 34 units that consist of 1.7M shares of common stock (1/9) |
Spectrum | Private | 0.225S | $0.506 | Spectrum raised $506,250 with the private placement of 225,000 shares with institutional investors (1/17) |
| | ||||
Notes: |
||||
This chart does not include real estate or manufacturing plant financings. |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
@ Dates refer to the date of the press release. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
N/A = Not available, applicable or reported. |
||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
